Novavax (NVAX) Other financing activities (2010 - 2022)
Novavax (NVAX) posted quarterly Other financing activities of -$983000.0 for Q3 2022, up 82.0% year-over-year from -$540101.2 in Q3 2021, and down 266.79% quarter-over-quarter from -$268000.0 in Q2 2022.
Novavax (NVAX) Other financing activities (2010 - 2022) Analysis & Trends
Novavax's Other financing activities history runs 13 years deep, the most recent figure standing at -$983000.0 for Q3 2022.
- In Q3 2022, Other financing activities rose 82.0% year-over-year to -$983000.0; the TTM figure through Sep 2022 stood at $3.4 million (up 138.12% YoY), while the FY2021 annual figure was $24.8 million, up 360.07% from the prior year.
- Other financing activities for Q3 2022 stood at -$983000.0, down from -$268000.0 in the prior quarter.
- The five-year high for Other financing activities was $26.8 million in Q3 2020, with the low at -$30.3 million in Q4 2020.
- The 5-year median for Other financing activities is $942000.0 (2019), against an average of $2.0 million.
- Peak annual rise in Other financing activities reached 481880.0% in 2021, while the deepest fall reached 120.42% in 2021.
- Novavax's Other financing activities stood at $283000.0 in 2018, then plunged by 82.33% to $50000.0 in 2019, then slumped by 60752.0% to -$30.3 million in 2020, then surged by 110.95% to $3.3 million in 2021, then plunged by 129.61% to -$983000.0 in 2022.
- Business Quant data shows NVAX's Other financing activities at -$983000.0 in Q3 2022, -$268000.0 in Q2 2022, and $1.3 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -983,000.00 |
| Sep 30, 2022 | -983,000.00 |
| Jun 30, 2022 | -268,000.00 |
| Jun 30, 2022 | -268,000.00 |
| Mar 31, 2022 | 1.32 Mn |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | -5.46 Mn |
| Sep 30, 2021 | -5.46 Mn |
| Jun 30, 2021 | 2.80 Mn |
| Jun 30, 2021 | 2.80 Mn |
| Mar 31, 2021 | 24.10 Mn |
| Mar 31, 2021 | 24.10 Mn |
| Dec 31, 2020 | -30.33 Mn |
| Dec 31, 2020 | -30.33 Mn |
| Sep 30, 2020 | 26.75 Mn |
| Sep 30, 2020 | 26.75 Mn |
| Jun 30, 2020 | 8.95 Mn |
| Jun 30, 2020 | 8.95 Mn |